Andere Sprachen CanSino Biologics Inc. Shanghai S.E.

Aktien

688185

CNE100004BM0

688185

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 31.05.2024			% 5 Tage	% 1. Jan.
49.31 ^CNY	-0.48%		-3.60%	-33.83%

31.05.	CanSino Biologics Inc. gibt den Rücktritt von Nisa Bernice Wing-Yu LEUNG als Non-Executive Director und Mitglied des Nominierungsausschusses bekannt	CI
21.05.	Cansino Biologics investiert 160 Millionen Yuan in strukturierte Einlagen der China Bohai Bank	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee	31.05.
Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	21.05.
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29.04.
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	22.04.
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	21.03.
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20.03.
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	28.02.
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	26.02.
Cansino Biologics Inc. Announces Board and Committee Elections	23.02.
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23.02.
CanSino Biologics Deconsolidates CanSino SPH	02.02.
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	31.01.
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	31.01.
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	30.01.
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	30.01.
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	15.01.
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20.12.
Scientists see risk of lost opportunity for long COVID research in China	14.12.
Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult	06.12.
CanSino Biologics Inc. announces Recombinant Covid-19 Xbb.1.5 Variant Vaccine Forinhalation (Adenovirus Type 5 Vector) Included for Emergency Use	03.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

CanSino Biologics über AstraZeneca-Deal und Ergebnis

Am 31. August 2023 um 12:08 Uhr